Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance

AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lilly’s rival therapy Jardiance.